Filing Flows › Foghorn Therapeutics (FHTX) › Q3 2025
Foghorn Therapeutics (FHTX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Foghorn Therapeutics (FHTX) reported revenue of $8.2M for the third quarter 2025 (Q3 2025), +4% from a year earlier and +8% from the quarter before. Operating margin was -226.9%, net loss $15.8M (194.4% of revenue).
Foghorn Therapeutics, Q3 2025: revenue $8.2M (+4% year over year), operating margin -226.9%, net loss $15.8M, operating cash flow −$18.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.2M | +8% | +4% |
| Operating profit | −$18.5M | — | — |
| Net earnings | −$15.8M | — | — |
| Operating cash flow | −$18.9M | — | — |
What changed
Revenue was $8.2M in Q3 2025, up 4% year over year and up 8% from the previous quarter.
Operating costs exceeded revenue by $18.5M, an operating margin of -226.9%. Total costs fell 16% while revenue rose 4%. The quarter ended with a net loss of $15.8M, narrower than the previous quarter's $17.9M loss.
Operating cash flow was −$18.9M. Non-cash charges added back $900K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $6.6M.
Questions
What was Foghorn Therapeutics' revenue in the third quarter 2025?
Foghorn Therapeutics (FHTX) reported revenue of $8.2M for the third quarter 2025 (Q3 2025), +4% from a year earlier and +8% from the quarter before.
Was Foghorn Therapeutics profitable in the third quarter 2025?
Operating loss was $18.5M (-226.9% of revenue) and net loss $15.8M.